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Introduction: In this study, we evaluated the safety and pharmacodynamic effects of the Fc-inactivated
anti-β-amyloid (anti-Aβ) monoclonal antibody GSK933776 in patients with mild Alzheimer’s disease and mild
cognitive impairment. Aβ and tau levels were investigated in cerebrospinal fluid (CSF), and the relationship
between Aβ levels and Aβ modulation in plasma was explored. The feasibility of a continuous sampling method
using a lumbar catheter was assessed.
Methods: This trial was a phase I, open-label, uncontrolled, single-dose, exploratory experimental medicine study
of intravenous GSK933776 at doses of 1 mg/kg, 3 mg/kg or 6 mg/kg (n = 6/group). The time course of plasma
and CSF concentrations of GSK933776 and Aβ was assessed. Sample size was based on feasibility, and no formal
statistical analyses were performed.
Results: Following administration of GSK933776 at doses of 1 mg/kg, 3 mg/kg and 6 mg/kg, there were decreases
from baseline in CSF Aβ1–42 (from 0 to 12 hours) by 22.8 pg/ml (6.2%), 43.5 pg/ml (9.2%) and 60.5 pg/ml (12.5%),
respectively. Plasma concentrations of total Aβ18–35 and Aβ4228–42 increased immediately after infusion and CSF
tau concentration increased slightly, but did not significantly change, following administration of all doses of
GSK933776. Pharmacokinetics confirmed the presence of GSK933776 in the CSF, which exhibited a dose–response
relationship. One patient underwent minor surgery without sequelae following a ruptured lumbar catheter.
Conclusion: GSK933776 demonstrated pharmacological activity and target engagement in CSF and plasma,
and the continuous sampling method via a catheter successfully assessed the Aβ changes following single-dose
administration of GSK933776.
Trial registration: ClinicalTrials.gov Identifier: NCT01424436. Registered 4 August 2011Introduction
Aggregated β-amyloid peptide (Aβ) is the hallmark of
Alzheimer’s disease (AD) brain pathology. As Aβ plaques
are one of the underlying pathological features of AD, sig-
nificant research efforts have been directed at developing
antiamyloid therapies to clear or neutralise the amyloid
peptide’s toxic forms [1,2]. Immunotherapeutic approaches* Correspondence: prafull.c.mistry@gsk.com
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which produces an immune response against Aβ. Activation
of both cellular and humoral immunity follows, which clears
amyloid deposits from the brain. Passive immunisation
involves administration of exogenous, specific monoclo-
nal antibodies against Aβ which may treat AD by acting
centrally on amyloid plaques in the brain or peripherally
through an Aβ “peripheral sink” mechanism. By the per-
ipheral sink mechanism, circulating antibodies sequester
Aβ and favour efflux of Aβ from the central nervous
system (CNS) over influx to the CNS [3].td. This is an Open Access article distributed under the terms of the Creative
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against Aβ is considered to be the preferred method in the
search for mechanistic disease-modifying treatments for
AD. The key element for an immunotherapy during early
clinical development is to demonstrate that the agent
engages its target. In the case of anti-Aβ antibodies, the
preferred target is the CNS. During the development of
the human anti-Aβ antibody gantenerumab, it was initially
demonstrated in mice that the antibody bound specifically
to Aβ plaques [4]. In an ascending-dose, positron emission
tomographic study of patients with AD and in ex vivo
studies of human brain slices taken from patients who had
AD, gantenerumab treatment resulted in reduction of
brain Aβ levels, indicating that antibody–Aβ complexes
had formed [4]. Cerebrospinal fluid (CSF) examinations
conducted in patients with AD following administration
of solanezumab, another human anti-Aβ antibody, showed
a dose-dependent increase in unbound CSF Aβ1–42,
suggesting that this antibody shifted the Aβ equilibrium
sufficiently to mobilise Aβ1–42 from amyloid plaques [5].
Two approaches are being used in AD clinical trials to
obtain CSF samples to assess drug penetration and target
engagement in the CNS. The lumbar puncture technique
relies on sampling at two different time points and was
used to determine CSF Aβ levels and drug concentrations
in a solanezumab phase II study [5]. Alternatively, CSF
samples can be taken continuously by using a catheter, as
demonstrated in a previous study, to measure Aβ produc-
tion and clearance in the CNS directly [6,7].
GSK933776 is a humanised mouse anti-human Aβ
IgG1 monoclonal antibody that binds with high affinity
to the Aβ N terminus and has the Fc region engineered
to substantially reduce the fixation of complement and
Fc receptor binding, which is responsible for humoral
adaptive immunity and cell-mediated tissue damage.
Herein we present the results of an exploratory experi-
mental medicine study conducted to assess the effects of
a single-dose exposure of GSK933776 on Aβ levels in
CSF, as well as its relationship with Aβ modulation, in
the plasma of patients with mild AD and mild cognitive
impairment (MCI). We assessed the time course and
dose-dependency of Aβ and tau changes in the first 12
hours after administration of GSK933776 as well as the
feasibility of using lumbar catheters to assess these
changes. The choice of dose ranges tested in this study
was driven by pharmacodynamics detected in a previous
study conducted in patients with AD. GSK933776 ad-
ministered in three repeat doses every 4 weeks at ≥0.1
mg/kg lowered free Aβ concentrations in plasma. For
total Aβ1–42, the final peak/trough ratio was ≤2 at
GSK933776 ≥ 3 mg/kg. For total Aβ18–35, the final peak/
trough ratio was ≤2 at 6 mg/kg (manuscript in submission).
The results of our present study will support the dose selec-




The study protocol was reviewed and approved by the
following ethics committees: Medizinische Ethik-Kommis-
sion II, der Medizinischen Fakultät Mannheim, Mannheim,
Germany; Ethik-Kommission der Medizinischen Fakultät
und am Universitätsklinikum Tübingen, Germany; and
Regionala Etiksprovningsnamnden Stockholm, Stockholm,
Sweden. The study was conducted in accordance with
Good Clinical Practice and the 2008 Declaration of
Helsinki. All patients provided written, informed consent
to participate in the study and, separately, to undergo
genetic analysis.
Study population
Men and nonfertile women ages 50 to 85 years with a
clinical diagnosis of probable mild AD, Mini Mental
State Examination (MMSE) score of 20 to 26 [8] or MCI
were included. All patients demonstrated a decrease in
Aβ1–42 to <550 pg/ml in CSF and increases in total T-
tau to >400 pg/ml or phosphorylated tau 181 to >70 pg/ml
in CSF, which are indicative of prodromal or mild AD
[9,10]. The term prodromal Alzheimer’s disease is used to
describe patients who have a hippocampal type of amnes-
tic disorder and a biomarker indicative of the presence of
AD, but who are not functionally impaired and do not
meet the criteria for Alzheimer’s dementia [11,12]. The
definition of prodromal AD is similar to that of MCI
based on the classification criteria proposed by the
National Institute on Aging and Alzheimer’s Association
work group [13].
The inclusion criteria for entry into this trial were that
patients had to be in good health, determined on the
basis of routine clinical laboratory test screening results,
physical examinations, vital signs and 12-lead electrocar-
diograms (ECGs). Exclusion criteria included a history
or evidence of any other CNS disorder that could be
interpreted as a cause of dementia; Hachinski Ischemic
Scale score >4; a magnetic resonance imaging (MRI)
scan not consistent with AD or evidence of any other
CNS condition; minimal vascular changes or more than
three microhaemorrhagic lesions; and a history of psy-
chiatric illness, cerebral haemorrhage, seizures or strokes
during the 3 years preceding the study; and cardiovascu-
lar disease or diabetes.
Study design
Recruitment of patients into this open-label, single-dose
study (protocol number BA1113043, Clinicaltrials.gov
Identifier NCT01424436) was carried out from May
2010 to December 2011 at three sites in Germany and
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to dosing and randomised to receive doses of GSK933776.
The patients were assigned to receive doses of GSK933776
in accordance with the randomisation schedule produced
using RandAll, a web server–based clinical trials system.
The doses of GSK933776 were 1 mg/kg, 3 mg/kg or 6 mg/
kg (n = 6 per group) administered by intravenous pump
infusion for 1 hour. Patients were followed for up to 56
days postdosing.
The primary endpoint was measurement of the levels
and temporal changes of Aβ1–42 in CSF after administra-
tion of GSK933776 in patients with mild AD and MCI.
Secondary endpoints were measurement of the levels
and temporal changes following GSK933776 administra-
tion of the following: total Aβ4228–42 and Aβ18–35 in
plasma and tau and phosphorylated tau 181 in CSF, the
pharmacokinetics for GSK933776 in CSF and plasma,
the pharmacokinetic–pharmacodynamic (PK–PD) rela-
tionship of GSK933776 in CSF and plasma and the
safety and tolerability of GSK933776.
Pharmacodynamics sample collection and analysis
For the first four patients who received the lowest dose
(1 mg/kg), blood and CSF samples were collected at
hourly intervals over a 30-hour time period from appro-
ximately 11 hours predosing to 19 hours postdosing.
The primary sampling time period for evaluation of
baseline levels was 6 to 8 hours predosing, whereby 0 to
5 hours postdosing was considered a run-in period
during which we obtained stable values. The time period
from 0 to 12 hours postdosing was the focus for the
postdosing assessment. This duration was initially based
on plasma pharmacodynamics observed in our previous
study, that is, the time of onset of lowering of free Aβ
(manuscript in submission). After the first four patients
completed the protocol, their Aβ levels were reviewed
and the sample collection times for CSF and blood for
both baseline and postdosing were adjusted as follows.
CSF samples were collected hourly (3 ml per sample)
from 9 hours predosing to 12 hours postdosing. Blood
samples were collected hourly from 6 hours predosing to 12
hours postdosing and at follow-up: once on day 7 and once
on day 56 postdosing. Total tau and phosphorylated tau 181
were measured in CSF at 5 hours predosing, at the time of
dosing and at 5 hours and 12 hours postdosing. Because of
the short-term exposure to GSK933776, no changes in total
tau or phosphorylated tau 181 were expected.
Insertion of the lumbar catheter was done according
to local hospital protocols. Continuous CSF collection
was performed according to the standard operating proce-
dures of the study and carried out by medical staff trained
in this procedure. CSF Aβ1–42, total tau and phospho-
rylated tau 181 were measured using INNOTEST kits
(Innogenetics/Fujirebio Europe, Ghent, Belgium). For theINNOTEST assay for Aβ1–42, we used 21F12 as a coating
monoclonal antibody, which is specific for the C-terminal
epitope 42, and 3D5 as a detection antibody, which is
specific to N-terminal epitope 1. The INNOTEST assay
for phosphorylated-tau 181 uses HT7 as a coating anti-
body, which is specific for amino acids 159 to 163, and
AT270 as a detection antibody, which is specific to phos-
phorylated Thr181. All CSF analyses were performed
batchwise by board-certified laboratory technicians who
were blinded to clinical and treatment data. Intra-assay
coefficients of variation were below 10%.
For plasma preparation, blood samples were processed
within 30 minutes by centrifugation at 2,000 × g for 15
minutes at 4°C to obtain plasma. A protease inhibitor
(0.02 ml; Roche Applied Science, Burgess Hill, UK) was
added to 0.5 ml of plasma. Samples were then frozen
upright on dry ice or in a freezer at or below −70°C. The
specificities of the capture and detection antibodies used
in the plasma total Aβ measurements (numbers in
brackets indicate the minimal amino acid sequence
detected by the plasma Aβ assay) were as follows. The
combinations of the capture antibody 6F6 (amino acids
28 to 35, generated by GlaxoSmithKline (GSK)) and
detection antibody 5G5 (amino acids 35 to 42; generated
by GSK) detected all Aβ fragments containing an intact
C terminus, such as Aβ1–42 and Aβ3–42, which is consid-
ered indicative of total Aβ4228–42. 6F6 and the detection
antibody 4G8 (amino acids 18 to 22) (SIG-39220;
Covance, Emeryville, CA, USA) detected Aβ fragments
containing the amino acid sequence 18 to 35, including
Aβ1–38, Aβ1–40 and Aβ1–42, which are considered indica-
tive of total Aβ18–35. Total assays detected both free and
GSK933776-bound Aβ fragments. There was no competi-
tion between the capture antibody 6FS and GSK933776,
because 6F6 recognises Aβ amino acids 28 to 35 and
GSK933776 recognises Aβ amino acids 1 to 5. Total
levels of Aβ18–35 and total Aβ4228–42 were measured
in plasma only.
Pharmacokinetics sample collection and analysis
Blood samples were collected once prebaseline, once
during GSK933776 administration, hourly for 4 hours
postdosing and then 6, 8, 10 and 12 hours postdosing as
well as at follow-up 7 and 56 days postdosing. CSF
samples were collected every hour over a total period of
22 hours, beginning 9 hours predosing and ending 12
hours postdosing. Approximately 0.5 ml of CSF and
approximately 3 ml of whole blood were collected at
every time point.
Concentrations of GSK933776 were determined in
plasma and CSF samples using an immunoassay that
detects free GSK933776 antibody. Briefly, the humanized
monoclonal antibody drug specific to GSK933776 is
captured with a Aβ fragment immobilized on a microtitre
Figure 1 Summary of patient screening. Aβ: β-amyloid; CSF:
Cerebrospinal fluid; MMSE: Mini Mental State Examination; MRI:
Magnetic resonance imaging; P-tau: Phosphorylated tau. 1Three
patients were screened twice therefore 29 screening evaluations
were conducted. 2Three patients received GSK933776 at two dose
levels; therefore, GSK933776 was administered 18 times.
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material and GSK933776 is detected using an anti-human
IgG (Fc specific) monoclonal antibody conjugated to a
reporter tag which is developed and detected by immu-
noelectrochemiluminescence, resulting in a quantifiable
response.
Pharmacokinetics analyses of plasma and CSF
GSK933776 were calculated by standard noncom-
partmental analysis using WinNonlin Pro 5.2 software
(Pharsight, Mountain View, CA, USA) and were based on
actual sampling times. The following parameters were
measured: the first occurrence of the maximum observed
plasma and CSF concentrations determined directly from
raw concentration–time data (Cmax); the time at which
Cmax was observed, which was determined directly from
raw concentration–time data (tmax); the area under the
plasma and CSF concentration–time curve to the last
quantifiable concentration (AUC0–t); the area under the
plasma and CSF concentration–time curve from time 0 to
12 hours postdosing (AUC0–12); the time of the last ob-
served plasma concentration (tlast); and the concentration
at tlast (Ct). The following additional parameters were
included for analysis of CSF pharmacokinetics: the areas
under the CSF concentration–time curve from time 0 to 4
hours postdosing AUC0–4 and from 5 to 12 hours post-
dosing AUC5–12 and the time prior to the first measurable
(that is, nonzero) concentration in CSF (tlag).
Safety assessments
Clinical chemistry and haematology tests, vital signs,
12-lead ECG readings and brain MRI were performed
at screening, at intervals throughout the study and at
follow-up examinations. Adverse events were coded using
the Medical Dictionary for Regulatory Activities (http://
www.meddra.org/) criteria.
Statistical analysis
As this was an exploratory experimental medicine study,
we did not perform any formal calculations of power or
sample size. Sample sizes were chosen based on feasibil-
ity to allow preliminary evaluations of the safety and
effects GSK933776 on Aβ and tau levels in CSF. No
formal statistical analyses were performed.
Pharmacodynamics analyses
CSF Aβ parameters were summarised using standard
descriptive statistics for a range of summary measures
(absolute, absolute change from baseline, absolute per-
cent change from baseline, weighted mean, weighted
mean change from baseline and weighted mean percent
change from baseline) and are presented in individual
participant plots. The weighted means were derived by
calculating the AUCs using the trapezoidal rule and
then dividing by the actual relevant time interval. CSFparameters (tau and phosphorylated tau 181) and
plasma parameters (Aβ18–35 and Aβ4228–42) were sum-
marised (absolute) and are presented in individual
participant plots Additional file 1 and Additional file 2,
respectively.
Pharmacokinetics analyses
Concentrations of GSK933776 in plasma and CSF were
summarised using standard summary statistics. Non-
compartmental plasma pharmacokinetics parameters were
summarised using standard descriptive statistics, which
also included coefficients of variation, geometric means
and 95% confidence intervals, for the geometric means.
Results
Patient disposition and baseline characteristics
Twenty-six patients were screened. Nine patients were
excluded because they failed to meet the inclusion cri-
teria, and two withdrew before dosing began (Figure 1).
Fifteen patients received GSK933776. Three of the fifteen
patients received GSK933776 at two dose levels. One pa-
tient received 1 mg/kg and 3 mg/kg one received 1 mg/kg
Table 1 Summary of patient baseline characteristicsa
GSK933776 dose
Demographic characteristics Sex 1 mg/kg (n = 6) 3 mg/kg (n = 6) 6 mg/kg (n = 6)
Mean age (yr) (range) 69.0 (61 to 79) 68.3 (57 to 79) 66.0 (58 to 77)
Sex, n (%) Female 2 (33) 5 (83) 3 (50)
Male 4 (67) 1 (17) 3 (50)
Race, n (%) Caucasian 6 (100) 6 (100) 6 (100)
Mean BMI kg/m2 (range) 23.7 (20 to 26) 23.5 (21 to 28) 25.4 (22 to 27)
APOE ε4 status, n (%) E2E3 0 (0) 0 (0) 0 (0)
E3E3 1 (17) 0 (0) 0 (0)
E3E4 3 (50) 2 (40)/1b 3 (75)c
E4E4 2 (33) 3 (60) 1 (25)
aBMI: Body mass index. bOne participant who entered the study and provided pharmacogenetics (PGx) consent and a sample in the 1 mg/kg dosing arm
reentered the study in the 3 mg/kg dosing arm. The PGx consent and sample were obtained again unnecessarily for the 3 mg/kg dosing. The second PGx sample
was subsequently destroyed to maintain consistency within the study by collecting and using only one sample per individual. cTwo participants who had entered
the study and provided PGx consent and a sample in the 3 mg/kg dosing arm reentered the study in the 6 mg/kg dosing arm. The PGx consent and sample were
not obtained again for these patients.
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For patients who were assigned to receive two dose
levels, the time interval between the doses was ap-
proximately 5 months. Their baseline data are pre-
sented in Table 1. For the entire patient population,
the mean age was 67.8 years (range: 57 to 70 years)
and the mean body mass index was 24.18 kg/m2
(range: 19.6 to 27.7). Nine patients were female and six
were male, and all were Caucasians. Most patients carried
the APOE ε4 allele (14 (93%) of 15 patients), and six of
these patients carried two copies of the allele.
Mean ± standard deviation (SD) CSF concentrations
for phosphorylated tau 181 were 90.6 ± 39.36 pg/ml for
the GSK933776 1 mg/kg group (n = 4), 71.0 ± 39.75 pg/ml
for 3 mg/kg (n = 5) and 153.9 ± 37.37 pg/ml for 6 mg/kg
(n = 6). Mean (±SD) CSF concentrations for tau were
828.3 ± 430.29 pg/ml for the GSK933776 1 mg/kg group
(n = 4), 668.2 ± 262.35 pg/ml for 3 mg/kg (n = 5) and
1,209.3 ± 262.35 pg/ml for 6 mg/kg (n = 6). Baseline data
for patient CSF Aβ1–42 levels are presented in Table 2.Table 2 Summary statistics of decreases from baseline in cere
GSK933776a
Sampling time (h) GSK933776 (n = 6/dose) Baselineb
0 to 4 1 mg/kg 363.4 ± 60
3 mg/kg 479.2 ± 65
6 mg/kg 502.7 ± 71
5 to 12 1 mg/kg 363.4 ± 60
3 mg/kg 479.2 ± 65
6 mg/kg 502.7 ± 71
0 to 12 1 mg/kg 363.4 ± 60
3 mg/kg 479.2 ± 65
6 mg/kg 502.7 ± 71
aCI: confidence interval. Results are reported as means ± standard deviations. b-6 toPharmacodynamics
Following administration of GSK933776 1 mg/kg, 3 mg/kg
and 6 mg/kg, average apparent decreases from baseline in
total CSF Aβ1–42 (0 to 12 hours) of 22.8 pg/ml (6.2%), 43.5
pg/ml (9.2%) and 60.5 pg/ml (12.5%), respectively (Table 2).
We observed greater decreases from 5 to 12 hours and
lesser decreases from 0 to 4 hours compared with CSF
Aβ1–42 (0 to 12 hours) across the dose ranges. Among
individual patients, decreases from baseline in CSF
Aβ1–42 were observed across the sampling periods
after administration of GSK933776 at all dose levels.
Decreases were most marked at the 6 mg/kg dose
(Figure 2).
We observed increases in plasma concentrations of
total Aβ18–35 and total Aβ4228–42 following admi-
nistration of GSK933776 at 1 mg/kg, 3 mg/kg and 6
mg/kg doses, which began immediately after infusion
(Figure 3A and 3B). Increases at the 3 mg/kg and 6 mg/kg
dose levels were slightly greater than those after the
1 mg/kg dose.brospinal fluid Aβ1–42 following administration of
Postdosing Change (%) 95% CI
.1 350.2 ± 61.7 −3.6 (−10.8 to 3.6)
.8 446.4 ± 70.8 −6.8 (−14.9 to 1.2)
.1 456.1 ± 88.9 −9.7 (−15.4 to −3.9)
.1 333.9 ± 52.1 −7.9 (−12.6 to −3.2)
.8 428.9 ± 77.1 −10.7 (−20.2 to −1.2)
.1 433.5 ± 85.1 −14.2 (−19.8 to −8.6)
.1 340.6 ± 55.7 −6.2 (−11.2 to −1.1)
.8 435.7 ± 74.4 −9.2 (−17.9 to −0.5)
.1 442.2 ± 86.4 −12.5 (−18.0 to −7.0)
−1 hours predosing.
Figure 2 Plots illustrating cerebrospinal fluid β-amyloid Ab(1–42) levels for individuals by time and dose level for each dose group.
GSK: GSK933776. Patients = 6 per group.
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were variable and exhibited a small increase from baseline
following administration of all three doses of GSK933776,
but they did not significantly change (see Additional file 1
and Additional file 2, respectively). Three patients who
received 1 mg/kg GSK933776 underwent sampling for tau
for 18 hours. By 12 hours in these patients, the levels of
tau appeared to have increased slightly, then plateaued
and then began to decrease.
Pharmacokinetics
Because the CSF pharmacokinetics data were minimal,
median values were considered more appropriate to
summarise (Table 3). The t½ parameter could not be
determined, because there were insufficient CSF and
plasma samples to characterise adequately the switch
from the first to the terminal exponential phase. Median
exposure in the CSF was higher at 6 mg/kg than at1 mg/kg and 3 mg/kg. The value of AUC0 to 4 was
zero at all doses because only one patient provided
quantifiable values at each dose level. The pharma-
cokinetics profile of GSK933776 was variable in the
CSF and did exhibit a dose–response relationship.
For plasma pharmacokinetics, following intravenous
infusion of GSK933776 at the 1 mg/kg, 3 mg/kg and 6
mg/kg doses, Cmax values were 18.4 μg/ml, 104.0 μg/ml
and 158.2 μg/ml, and tmax values were 11.7 hours, 2.1
hours and 1.9 hours, respectively (Table 4). GSK933776
exposure appeared to increase with dose level (Table 4).
A delay in the detection of GSK933776 in CSF was
observed (median values of each dose group from 5.0
hours to 8.5 hours) compared with GSK933776 in
plasma, which was detected immediately. This delay was
reflected in the CSF/plasma ratios, which increased with
time and were in the range of 0 to 0.23%. There were no
relationships between changes from baseline in CSF Aβ
Figure 3 Plots illustrating total plasma β-amyloid levels of
individual patients by time and dose level. (A) β-amyloid (18–35)
Aβ18–35. (B) Aβ28–42. GSK: GSK933776. Patients = 6 for each
dose group.
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fore, no PK/PD modelling was performed.
Safety
A summary of the most frequently reported adverse
events is given in Table 5. Two patients experienced
serious adverse events, neither of which was considered
by the investigator to be related to GSK933776. One
patient who received 3 mg/kg GSK933776 experienced a
procedure-related headache that started approximately
5.5 hours before administration of GSK933776. That
73-year-old patient was unable to eat and drink, was
admitted to the hospital 5 days later and was given
intravenous fluids and pain relief medication, and the
headache resolved 8 days later. One patient required surgi-
cal treatment to remove part of a catheter that tore during
placement and therefore did not receive GSK933776. That
patient was admitted to the neurosurgery ward, and the
disrupted piece of the catheter was removed after incision
of the skin. The catheter was broken in soft tissue, and no
subsequent infection or other complications occurred. The
adverse event thus resolved, and the patient was discharged
from the hospital the following day and was withdrawn
from the study. No clinical laboratory values were reported
as adverse events. One patient experienced two episodes of
atrial fibrillation during GSK933776 treatment, neither
of which was considered to be related to GSK933776
administration. One patient who received GSK933776
(6 mg/kg) had positive results in the binding antibody
and neutralising antibody tests at the follow-up visit
56 days after the first dose.
Discussion
Our findings in this study support target engagement of
GSK933776 in CSF. The patients’ baseline levels of CSF
Aβ1–42 were stable, and there were apparent decreases
following all doses of GSK933776 from baseline in
CSF Aβ1–42. These decreases seem to have been dose-
dependent, with greater reductions associated with higher
doses of GSK933776, and time-dependent, with greater
reductions occurring 5 hours after administration. In
contrast to a previous study, no diurnal variation in CSF
Aβ levels was observed [14]. CSF tau levels increased
slightly during this study, but the reason for this is
unknown. It could be related to the total volume of CSF
sampled and mobilisation of ventricular CSF to the lum-
bar sac. Tau concentrations in ventricular CSF are about
five times higher than in lumbar CSF [15].
We observed an increase in both total Aβ18–35 and
total Aβ4228–42 concentrations in plasma following
GSK933776 treatment. The pharmacokinetics data con-
firmed the presence of GSK933776 in CSF, which suggests
a central mechanistic model of action rather than a
peripheral sink mechanism. Although these two theories
Table 3 Noncompartmental pharmacokinetics in cerebrospinal fluid by dose following single dosing with GSK933776a
Parameters Median (range)
1 mg/kg (N/n = 6/3) 3 mg/kg (N/n = 6/6) 6 mg/kg (N/n = 6/4)
AUC0–4 (h∙mg/ml) 0.0 (0.0 to 71.1) 0.0 (0.0 to 32.1) 0.0 (0.0 to 38.9)
AUC5–12 (h∙mg/ml) 87.9 (12.7 to 134.9) 54.8 (6.3 to 398.8) 140.2 (49.1 to 626.5)
AUC0–12 (h∙mg/ml) 87.9 (12.7 to 210.9) 54.8 (6.3 to 456.0) 140.2 (49.1 to 703.9)
AUC0–t (h∙mg/ml) 6.3 (0.0 to 339.5) 54.8 (6.3 to 456.0) 88.1 (0.0 to 703.9)
Cmax (μg/ml) 12.7 (0.0 to 47.8) 20.1 (12.5 to 84.1) 28.5 (0.0 to 116.9)
Ct (μg/ml) 19.0 (11.4 to 25.3) 19.6 (12.5 to 84.1) 47.9 (18.6 to 116.1)
tmax (h) 10.0 (2.0 to 11.0) 11.8 (10.0 to 12.0) 12.0 (11.0 to 12.0)
tlast (h) 17.0 (11.0 to 19.0) 12.0 (11.6 to 12.0) 12.0 (12 to 12)
tlag (h) 8.0 (0.0 to 10.0) 8.5 (2.0 to 11.0) 5.0 (2.0 to 8.0)
aAUC0–4: Area under the cerebrospinal fluid (CSF) concentration–time curve from time 0 to 4 hours postdosing; AUC0–12: Area under the CSF concentration–time
curve from time 0 to 12 hours postdosing; AUC5–12: Area under the CSF concentration–time curve from 5 to 12 hours postdosing; AUC0–t: Area under the CSF
concentration–time curve to the last quantifiable concentration; Cmax: Maximum CSF concentration; Ct: Concentration at tlast; N: Number of patients who received
GSK933776; n: Number of patients from whom quantifiable CSF pharmacokinetics concentration levels were obtained and analysed; tlast: Time of the last observed
CSF concentration; tmax: Time of occurrence of Cmax; tlag: Time prior to the first measurable (that is, nonzero) concentration in CSF.
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http://alzres.com/content/6/2/19are popular in the mechanism of action of AD vaccin-
ation, they are not mutually exclusive. Further studies are
required to characterise the mechanistic model of
GSK933776 mode of action early and late after treatment.
The findings regarding GSK933776 plasma pharma-
cokinetics in this study are consistent with those in
previous solanezumab single- and multiple-dose studies
[5,16]. In all of these studies, maximum drug plasma
concentrations increased with drug dose levels [5,16].
Also, long terminal elimination half-lives were observed,
which is typical of a monoclonal antibody with low plasma
clearance. AUC0–∞ and t½ values were not calculated in
this study, because more samples would have been
required to characterise adequately the switch from the
first to the terminal exponential phase. In a previous study
of GSK9933776, however, a long terminal elimination
half-life (average range: 10 to 15 days) was observed
(manuscript in submission). The increase in plasma levels
of total Aβ18–35 and Aβ28–42 did not exhibit an apparent
dose–response relationship during the short observation
time in this study.Table 4 Noncompartmental pharmacokinetics in plasma follo
Geom
Parameters 1 mg/kg (N/n = 6/6) 95% CI 3 mg/kg (N
AUC0–12 (h∙mg/ml) 0.2 (26.0) 0.1 to 0.2 1.0 (19
AUC0–t (h∙mg/ml) 3.3 (39.3) 2.2 to 4.9 23.0 (1
Cmax (μg/ml) 18.4 (29.0) 13.6 to 24.9 104.0 (2
Ct (μg/ml) 0.5 (366.0) 0.1 to 2.5 1.2 (33
tlast (h) 909.8 (105.5) 367.0 to 2,255.4 1,337.4
tmax (h) 11.7 (264.1) 2.6 to 53.1 2.1 (16
aAUC0–12: Area under the plasma concentration–time curve from time 0 to 12 hours
last quantifiable concentration; CI: Confidence interval; Cmax: Maximum plasma conc
observed plasma concentration; tmax: Time of occurrence of Cmax.This study confirms the presence of GSK933776 in
CSF. CSF versus plasma ratios increased with time and
were ranged from 0 to 0.23%, reflecting the delay of
detection of GSK933776 in CSF by 5.0 hours to 8.5 hours
(median values in dose groups).
This study has several limitations. The decreases from
baseline in CSF Aβ1–42 were greater with the higher dose
of GSK933776 (6 mg/kg) than with the 1 mg/kg and
3 mg/kg dose groups. However, this result might have
been driven by the higher baseline CSF Aβ1–42 values
in the 6 mg/kg group compared with the other groups.
Differing baseline CSF Aβ1–42 values were also observed
between the other dose groups. However, all dose groups
showed similar trends in CSF Aβ1–42 changes over time,
regardless of baseline CSF Aβ1–42 values, suggesting that
this limitation did not affect the interpretability of the
data. This study also has a small sample size and is not
formally powered; therefore, we conducted no formal
statistical analyses. Despite the feasibility-driven limited
sample size in this study, our sample size is similar to
those of other published studies in the field [6,7]. Inwing single dosing with GSK933776a
etric mean (CV in %)
/n = 6/6) 95% CI 6 mg/kg (N/n = 6/6) 95% CI
.5) 0.9 to 1.3 1.6 (20.6) 1.3 to 2.0
2.8) 20.2 to 26.3 36.3 (15.3) 31.0 to 42.6
0.0) 84.4 to 128.1 158.2 (24.0) 123.8 to 202.1
.0) 0.9 to 1.7 1.5 (30.0) 1.1 to 2.1
(0.2) 1,335.1 to 1,339.8 1,417.2 (7.0) 1,317.6 to 1,524.3
.4) 1.8 to 2.5 1.9 (61.2) 1.1 to 3.4
postdosing; AUC0–t: Area under the plasma concentration–time curve to the
entration; Ct: Concentration at tlast; CV: Coefficient of variation; tlast: Time of last
Table 5 Summary of the most frequently reported adverse
eventsa
GSK933776 dose






Any event 3 (50) 5 (83) 5 (83)
Fatigue 0 2 (33) 2 (33)
Headache 1 (17) 4 (67) 2 (33)
Nausea 0 3 (50) 1 (17)
Vomiting 0 2 (33) 1 (17)
Back pain 1 (17) 2 (33) 1 (17)
Nasopharyngitis 0 0 0
Neck pain 0 1 (17) 1 (17)
Atrial fibrillation 1 (17) 0 1 (17)
Procedural headache 0 1 (17) 1 (17)
aData in parentheses are percentages.
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have interfered with Aβ in the CSF Aβ1–42 assay. The
potential for spurious results induced by any possible
interaction of GSK933776 with the CSF Aβ1–42 assay was
not assessed, thus limiting the interpretation of the results.
However, there was no apparent relationship between
changes from baseline in CSF Aβ and any CSF pharmaco-
kinetics parameters. The differences in mean baseline CSF
Aβ levels observed between the dose groups were most
likely due to chance resulting from the small sample size.
The observed frequency of APOE ε4 carriers was
higher in this study (14 (93%) of 15 patients) than in a
typical AD population (64.8%) [17]. This difference
could be due to the small number of patients in this
study and the screening selection criteria pertaining to
reductions in Aβ and increases in tau levels in the CSF.
Other contributing factors could be the age of the pa-
tients and/or the MMSE score ranges. In this study, no
APOE ε4 data were obtained from patients who failed
screening, because pharmacogenetic samples were taken
only from patients who were randomised.
We believe that, to the best of our knowledge, this
study is one of very few intervention studies in which
the feasibility of using the CSF catheter to assess short-
term Aβ changes has been investigated. One catheter-
related serious adverse event occurred during the catheter
insertion procedure in our study.
The outcomes of phase III studies conducted with the
Aβ monoclonal antibodies bapineuzumab and gantener-
umab, as well as another pivotal study carried out with
solanezumab, have failed to demonstrate unambiguous
efficacy in patients with mild to moderate AD, but they
have triggered significant new activity in the study of
earlier stages of AD.Conclusions
The results of this study support pharmacological activ-
ity and target engagement of GSK933776 in both CSF
and plasma. They demonstrate that the continuous sam-
pling method using a catheter can be used successfully
to assess Aβ changes after single-dose administration of
an anti-Aβ antibody in patients with mild AD or MCI.
Additional files
Additional file 1: Individual patient plots of cerebrospinal fluid tau
by time and dose level. GSK: GSK933776. Coloured dashed lines refer to
each individual patient plot.
Additional file 2: Individual patient plots of cerebrospinal fluid
phosphorylated tau 181 by time and dose level. GSK: GSK933776;
P-TAU: Phosphorylated tau. Coloured dashed line refers to each individual
patient plot.
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